Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Breast Cancer Detection Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Roger Zucchet who wrote (7)	10/12/1998 3:52:00 PM
From: Profiteer	Read Replies (2) \| Respond to of 40

Roger.. I do not follow BZET. Their thread has all but been abandoned from what I can see. Last post was July 6th. COII expects to receive fully reporting SEC status by the end of this month,October. It has been in FDA clinical trials now for over a year and has it's requirements about completed... In my opinion, CTI out performs all Early Breast Cancer detection equipment and has been climbing steadily in it's stock value... My advice: LOCK ONTO IT BEFORE IT'S OUT OF REACH... A lot of good research on the COII information thread and at their Website. www.cti-net.com

To: Roger Zucchet who wrote (7)	10/12/1998 8:48:00 PM
From: M&A West, Inc.	Respond to of 40

Lifeline BioTechnologies Selected as One of 80 Worldwide to Participate in Discovery Expo '98, October 20, in New York City RENO, Nev.--(BW HealthWire)--Oct. 12, 1998--Lifeline BioTechnologies, Inc. (OTC BB:LBTI) will be among 80 of the top growth companies in the world to gather October 20 at Discovery Expo '98 to meet 1,000 Wall Street movers and shakers at the New York Hilton and Towers. This sixth in a unique series of Discovery Expos was organized by the Investment Reporter, a Newport Beach, Calif.-based financial newspaper, to bring together undiscovered companies with high-profile growth fund managers, analysts, stockbrokers and sophisticated investors in a one-day event. These key players will have a chance to become acquainted with the products, top executives and future outlook of participating NASDAQ and OTC Bulletin Board listed firms whose stock represents opportunities for appreciation. ''When you're a mid-cap or small-cap company you tend to fall off the financial radar screen no matter how well you're doing financially,'' said John Robbins, publisher of The Investment Reporter, host of the Discovery Expos. ''The financial world needs to find growing companies whose shares have further upside potential and these companies want to be discovered. Expo '98 is a convenient way for them to find each other.'' Lifeline BioTechnologies, Inc.'s (Lifeline) has developed a non-invasive test for early breast cancer detection. The test is incorporated into a proprietary product called First Warning(TM). In preliminary pilot studies, First Warning(TM) demonstrated great promise in detecting formation of extremely early stage breast lesions, particularly in younger women. The second product division under Lifeline BioTechnologies is a line of nutritional food supplements packaged and sold under the tradename NATURE'S CREATIONS. These supplements are marketed and directed towards people afflicted with degenerative diseases that are commonly found in the aging population. These diseases include cancer (breast, colon and prostate) cardiovascular, osteoporosis and mental alertness. --------------------------------------------------------------------------------